Fundz

Promis Neurosciences Announces $20.4 Million Private Placement Financing

PUBLIC · PMNAug 21, 2023

Amount Raised

$20.4 Million

Round Type

Post-IPO Equity

TorontoBiotechnology

Description

ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has entered into a securities purchase agreement with certain new and existing accredited investors to issue and sell an aggregate of approximately $20.4 million of (a) common share units, each consisting of one of the Company’s common shares (the “Common Shares”) and one warrant to purchase one Common Share (the “Warrants”) (the “Common Share Units”) and (b) pre-funded units, each consisting of one pre-funded warrant to purchase one Common Share and one Warrant (the “Pre-Funded Units”). The Common Share Units were sold at a price of $1.88 per unit and the Pre-Funded Warrants were sold at a price of $1.87 per unit through a private investment in public equity (“PIPE”) financing.

Quick answer

ProMIS Neurosciences raised $20.4 Million in a Post-IPO Equity round, dated August 21, 2023. ProMIS Neurosciences is based in Toronto, Ontario, Canada.

How much did ProMIS Neurosciences raise?
ProMIS Neurosciences raised $20.4 Million in a Post-IPO Equity round on August 21, 2023.
What does ProMIS Neurosciences do?
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of..
Where is ProMIS Neurosciences based and how big is it?
ProMIS Neurosciences is based in Toronto, Ontario, Canada. Fundz records about 26 employees.
Who are the decision-makers at ProMIS Neurosciences?
Fundz holds 1 contact at ProMIS Neurosciences, including the Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as ProMIS Neurosciences that raised within 45 days of this round, from Fundz verified event records.

  • Oncodesign Precision Medicine raised an undisclosed amount (Funding Round) on October 5, 2023.
  • LyGenesis raised $18M on October 5, 2023.
  • Integral Molecular raised $900K (Seed) on October 5, 2023.
  • Inovedis raised an undisclosed amount (Series A) on October 5, 2023.
  • Experic raised an undisclosed amount (Series B) on October 5, 2023.
  • Interius raised $21M on October 5, 2023.

Who to call at ProMIS Neurosciences, and when

A new round usually means ProMIS Neurosciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day ProMIS Neurosciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at ProMIS Neurosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at ProMIS Neurosciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

ProMIS Neurosciences

Location

1920 Yonge St., Suite 200

Toronto, Ontario, Canada

About

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, predicts novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment ProMIS Neurosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsEugene W., DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for ProMIS Neurosciences's next move

See what Strategic adds

ProMIS Neurosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.